These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11418381)

  • 21. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
    Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft.
    De Souza CA; Durães MI; Vigorito AC; Penteado Aranha FJ; Oliveira GB; De Brito Eid KA; Zulli R; Cristina E; Miranda M; Botega NJ
    Haematologica; 2002 Dec; 87(12):1281-5. PubMed ID: 12495902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
    Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases.
    Childs RW
    Cancer J; 2000; 6(3):179-87. PubMed ID: 10882334
    [No Abstract]   [Full Text] [Related]  

  • 31. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.
    Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
    Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
    Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial.
    Himmelmann B; Himmelmann A; Furrer K; Halter J; Schanz U
    Bone Marrow Transplant; 2002 Oct; 30(8):491-6. PubMed ID: 12379887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow and peripheral blood stem cell transplantation for malignancy.
    Johnson PW; Simnett SJ; Sweetenham JW; Morgan GJ; Stewart LA
    Health Technol Assess; 1998; 2(8):1-187. PubMed ID: 9728295
    [No Abstract]   [Full Text] [Related]  

  • 37. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow.
    Elfenbein GJ; Sackstein R
    Exp Hematol; 2004 Apr; 32(4):327-39. PubMed ID: 15050742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
    Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
    Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
    Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.